Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celtic Pours More Private Equity Into The Promise Of Antibody-Drug Conjugates

This article was originally published in Start Up

Executive Summary

Celtic Therapeutics will put as much as $50 million into ADC Therapeutics to develop next-generation cancer drugs based on assets from Spirogen, another of its other portfolio companies.

You may also be interested in...



Mersana Moves Into Antibody-Drug Conjugates With Endo Collaboration

Previously partnered with Teva on a small molecule drug conjugate, biotech says its focus going forward will be on developing ADCs, with partners and in-house.

Seattle Genetics Commits To Simultaneous Confirmatory Trials For Adcetris

FDA approves the antibody-drug conjugate for late stage Hodgkins lymphoma and systemic anaplastic large cell lymphoma Aug. 19.

ImmunoGen Wants A Bigger Share Of The Antibody-Drug Conjugate Pie

The company touted its proprietary pipeline at an investor day as it turns its focus away from partnerships and toward its internal research.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC092298

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel